ASCO 2018

Viewing 1-20 of 26 articles

ASCO 2018: Relapse-Free Survival of Clinical T2-4N0 Urothelial Bladder Carcinoma After Radical Cystectomy, with or without Perioperative Chemotherapy: Endpoints for Clinical Trial Design.

ASCO 2018: Optimization of PD-L1 Algorithm for Predicting OS in Patients with Urothelial Cancer Treated with Durvalumab

ASCO 2018: Tailoring of Chemotherapy to Fit Patients with Metastatic Urothelial Cancer

ASCO 2018: Targeted Therapies in Advanced Urothelial Cancer

ASCO 2018: Immunotherapy-Based Approaches for Advanced Urothelial Cancer

ASCO 2018: SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US

ASCO 2018: Bladder Cancer and Germ Cell Tumors

ASCO 2018: Nonimmunotherapy Strategies in Advanced Bladder Cancer

ASCO 2018: A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer (ABACUS)

ASCO 2018: Preoperative Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma: Interim Clinical and Biomarker Findings from the Phase 2 PURE-01 Study

ASCO 2018: Cctg BL12: Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing On or After a Platinum Containing Regimen

ASCO 2018: PECULIAR: An Open Label, Multicenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients with Muscle-invasive Urothelial Bladder Cancer

ASCO 2018: Updated Results from the Enfortumab Vedotin Phase 1 (EV-101) Study in Patients with Metastatic Urothelial Cancer

ASCO 2018: First Results from the Primary Analysis Population of the Phase 2 Study of Erdafitinib in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations

ASCO 2018: SPIRE: A Phase 1b/Randomized 2a Open Label Clinical Trial Combining Guadecitabine (SGI-110) with Cisplatin and Gemcitabine Chemotherapy for Solid Malignancies Including Bladder Cancer

ASCO 2018: Atezolizumab in First-Line Cisplatin-Ineligible or Platinum Treated Locally Advanced or Metastatic Urothelial Cancer: Long-Term Efficacy from Phase 2 Study IMvigor210

ASCO 2018: BMS-986205, an IDO1 Inhibitor, in Combination with Nivolumab: Updated Safety Across all Tumor Cohorts and Efficacy in Patients with Advanced Bladder Cancer

ASCO 2018: Apache: Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Advanced Germ Cell Tumors: Results at the End of First Stage

ASCO 2018: Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial

ASCO 2018: A Subgroup Analysis of the East Asia Population in RANGE

1
2

email news signup